On April 9, 2018 Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries, reported that its President & CEO Gerald E. Commissiong will present a corporate overview at The Microcap Conference on April 10, 2018 at 9:30am in Track 1 at the JW Marriott Essex House in New York, NY (Press release, Amarantus Biosciences, APR 9, 2018, View Source [SID1234525231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live at View Source and will be archived for 90 days following the presentation. Interested investors may contact the Company by email at [email protected] or by calling and leaving a message at 917-686-5317.

The Company’s CEO Gerald Commissiong, and interim-COO/CFO Barney Monte have remaining availability for one-on-one meetings with investors on Tuesday April 10, 2018.